Dougherty Paul J, Waring George, Chayet Arturo, Fischer Jeffery, Fant Barbara, Bains Harkaran S
Private Practice, Camarillo, Los Angeles, California, USA.
J Cataract Refract Surg. 2008 Nov;34(11):1862-71. doi: 10.1016/j.jcrs.2008.07.021.
To assess the efficacy, predictability, safety, and quality-of-life effects of topography-guided laser in situ keratomileusis (LASIK) for the correction of myopia with astigmatism using the EC-5000 CXII excimer laser equipped with a customized aspheric treatment zone algorithm.
Ophthalmology clinics in the United States and Mexico.
In a multicenter United States Food and Drug Administration study of topography-guided LASIK, 4 centers enrolled 135 eyes with a spherical manifest refraction error ranging from -0.50 to -7.00 diopters (D) and astigmatism ranging from 0.50 to 4.00 D. All eyes were targeted for emmetropia. Refractive outcomes, higher-order aberrations (HOAs), and contrast sensitivity were analyzed preoperatively and postoperatively. Patient satisfaction was assessed using 2 questionnaires.
Six months postoperatively, the mean manifest refraction spherical equivalent in all eyes was -0.09 D +/- 0.31 (SD); of the 131 eyes, 116 (88.55%) had an uncorrected visual acuity of 20/20 or better and 122 (93.13%) had an MRSE within +/-0.50 D. The best spectacle-corrected visual acuity (BSCVA) increased by 2 or more lines in 21 (16.03%) of 131 eyes; no eye lost 2 lines or more of BSCVA. The total ocular HOA increased by 0.04 microm. Patients reported significantly fewer night driving and glare/halo symptoms postoperatively than preoperatively.
Use of a customized aspherical treatment zone in eyes with myopia and astigmatism was safe, effective, and predictable and reduced symptoms associated with night driving, glare, and halos.
使用配备定制非球面治疗区算法的EC-5000 CXII准分子激光，评估地形引导的准分子原位角膜磨镶术（LASIK）矫正近视合并散光的疗效、可预测性、安全性及对生活质量的影响。
美国和墨西哥的眼科诊所。
在美国食品药品监督管理局的一项多中心地形引导LASIK研究中，4个中心纳入了135只眼睛，其球镜明显屈光不正范围为-0.50至-7.00屈光度（D），散光范围为0.50至4.00 D。所有眼睛的目标均为正视。术前和术后分析屈光结果、高阶像差（HOA）和对比敏感度。使用两份问卷评估患者满意度。
术后6个月，所有眼睛的平均明显屈光球镜等效值为-0.09 D±0.31（标准差）；在131只眼中，116只（88.55%）的未矫正视力为20/20或更好，122只（93.13%）的平均残余球镜等效值在±0.50 D以内。在131只眼中，21只（16.03%）的最佳矫正视力（BSCVA）提高了2行或更多；没有眼睛的BSCVA下降2行或更多。总的眼HOA增加了0.04微米。患者报告术后夜间驾驶以及眩光/光晕症状比术前明显减少。
在近视和散光眼中使用定制的非球面治疗区是安全、有效且可预测的，并减少了与夜间驾驶、眩光和光晕相关的症状。
